- Home
- QURE
QURE
uniQure N.V.
as of 12-05-2025 3:59pm EST
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases.
| Founded: | 1998 | Country: | Netherlands |
| Employees: | N/A | City: | AMSTERDAM |
| Market Cap: | 1.9B | IPO Year: | 2007 |
| Target Price: | $62.33 | AVG Volume (30 days): | 2.8M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 13 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -4.34 | EPS Growth: | N/A |
| 52 Week Low/High: | $6.14 - $71.50 | Next Earning Date: | 11-10-2025 |
| Revenue: | $15,751,000 | Revenue Growth: | -44.90% |
| Revenue Growth (this year): | -35.67% | Revenue Growth (next year): | 158.05% |
AI-Powered QURE Daily Prediction
Machine learning model trained on 25+ technical indicators
AI Recommendation
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of uniQure N.V. (QURE)
Director
Avg Cost/Share
$27.26
Shares
31,434
Total Value
$856,881.00
Owned After
55,739
Chief Financial Officer
Avg Cost/Share
$55.00
Shares
15,000
Total Value
$825,000.00
Owned After
217,730
SEC Form 4
CEO, Managing Director
Avg Cost/Share
$41.42
Shares
226,316
Total Value
$9,382,472.66
Owned After
826,454
Chief Financial Officer
Avg Cost/Share
$40.04
Shares
3,000
Total Value
$120,120.00
Owned After
217,730
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Gut Robert | QURE | Director | Nov 6, 2025 | Sell | $27.26 | 31,434 | $856,881.00 | 55,739 | |
| Kaye Jack | QURE | Director | Nov 4, 2025 | Sell | $30.34 | 38,810 | $1,177,517.30 | 20,439 | |
| KLEMT CHRISTIAN | QURE | Chief Financial Officer | Sep 26, 2025 | Sell | $55.00 | 15,000 | $825,000.00 | 217,730 | |
| Kapusta Matthew C | QURE | CEO, Managing Director | Sep 24, 2025 | Sell | $41.42 | 226,316 | $9,382,472.66 | 826,454 | |
| KLEMT CHRISTIAN | QURE | Chief Financial Officer | Sep 24, 2025 | Sell | $40.04 | 3,000 | $120,120.00 | 217,730 |
Compare QURE vs Leading Stocks
See how QURE stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "QURE uniQure N.V. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.